Lundbeck has received Fast Track designation from the U.S. FDA for Lu AH69593, its lead oral orexin 2 receptor agonist in ...

First patient randomised as study advances novel pan phosphate transporter inhibitor R1 Therapeutics has randomized the first ...

Mission Therapeutics has agreed to divest its phase 2‑ready acute kidney injury candidate MTX652 to Australian renal ...

Nouscom will present new phase 1b/2 data on its off‑the‑shelf cancer immunotherapy NOUS‑209 at the European Society for ...

Jasper Therapeutics has completed its all‑stock acquisition of Kira Pharmaceuticals, creating a combined business focused on ...

ViiV Healthcare will present a broad range of clinical and real-world data at AIDS 2026, highlighting progress across its integrase strand transfer inhibitor portfolio, including long-acting medicines ...

The Scottish Medicines Consortium has recommended Astellas’s VEOZA (fezolinetant) 45 mg once daily for the treatment of ...

Ardena has appointed Ariane de Ganck as Chief Scientific Officer, reinforcing its focus on scientific excellence across its ...

EpilepsyGTx has partnered with ClearPoint Neuro to enable targeted delivery of its lead gene therapy candidate, EPY201, ahead ...

Merck has announced that the European Commission has approved an update to the Erbitux (cetuximab) EU label, extending its ...

Braun has appointed Sophie Spencer as Social Value & ESG Specialist, recognising her rapid impact since joining the company ...

Eisai and Biogen have announced that the U.S. Food and Drug Administration has approved a supplemental biologics licence application for a once weekly subcutaneous initiation dose ...